A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with Durable Responses in Patients with HER2-mutated MBC By Ogkologos - January 29, 2025 821 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SGNTUC-019 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma Chemotherapy-Free Regimen of Targeted Agent and Immunotherapeutic Superior to Imatinib and Chemotherapy Among Adult Patients with Ph-positive ALL Meet the first recipient of the ESMO Artificial Intelligence Fellowship MOST POPULAR This Harmful Chemical Is Still Being Used In Popular Household Products June 15, 2021 Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly... April 20, 2026 A New Online Tool Predicts RFS and OS Probabilities in Patients... February 7, 2024 Adjuvant Atezolizumab Plus Bevacizumab Improves RFS Among Patients at High Risk... November 16, 2023 Load more HOT NEWS Marine Runs Five Marathons in Five Days to Help Fund Sister’s... Cancer “Decoys” Planted Underneath The Skin Lure In Cancer Cells And... Combination of Temozolomide and Capecitabine Associated with Improved PFS Compared to... Can Getting a “Base Tan” Protect You From Sunburn and Skin...
